Results 201 to 210 of about 45,512 (293)

Dynamic genetic and nongenetic RAS-pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy. [PDF]

Blood
Kennedy VE, Peretz CAC, Walia A, Chyla B, Sun Y, Hill J, Tran E, Koh AD, Ferng T, Pintar S, Jones MF, Popescu B, Lomeli I, Chehab F, Murad N, John A, Roy R, Olshen A, Berryhill CA, Davis C, Angus SP, Rivera JM, Meshulam A, Stieglitz E, Joshi S, Traer E, Dail M, Hamidi H, Altman JK, Daver N, Levis M, McCloskey J, Perl AE, Smith CC.   +33 more
europepmc   +1 more source

NRAS Mutation Analysis [PDF]

, 2020
openaire   +1 more source

Radiation‐induced AXL upregulation in CCR2+ monocytes promotes cardiac fibrosis

Clinical and Translational Medicine, Volume 16, Issue 10, October 2026.
1. IR_D30 is characterised by established cardiac fibrosis and ongoing immune remodelling. 2. Cardiac CCR2+ monocytes accumulate after irradiation and contribute to fibroblast activation through paracrine signalling. 3. AXL contributes to this fibroblast‐activating activity, at least in part through MEK/ERK signalling. 4.
Ying‐Yi Li, Jian‐Qi Xiong, Zhi‐Hui Zhang, Xin Liu, Yi‐Xin Cheng, Yong‐Xin Chi, Guan‐Qiao Li, Wen‐Huan Zhong, Shuang Chen, Zhen‐Yu He   +9 more
wiley   +1 more source

Recurrent and unusual infections unmasking a rare inborn error of immunity: a case report RAS-associated Autoimmune Lymphoproliferative Disease (RALD). [PDF]

BMC Pediatr
Ahmad Shawaludin MQ, Nik MAC, Zainudeen ZT, Taib F, Abd Hamid IJ.   +4 more
europepmc   +1 more source

One cycle of nelarabine given after induction is well tolerated but does not improve outcome in adults with T‐cell precursor acute lymphoblastic leukemia: Outcome data from the UKALL14 randomized‐controlled trial

HemaSphere, Volume 10, Issue 10, October 2026.
Abstract UKALL14 (NCT01085617) T‐cell arm was a phase 3, randomized‐controlled trial. Adults aged 25–65 years were randomized 1:1 at entry to receive standard of care (SOC) or SOC + nelarabine 1.5 g/m2 (Days 1, 3, and 5) to be administered following second induction. The primary end‐point was event‐free survival (EFS).
Clare J. Rowntree, Amy A. Kirkwood, Nadine Farah, Emma Lawrie, David I. Marks, Andrew K. McMillan, Tobias F. Menne, Anthony V. Moorman, Bela Patel, Pip Patrick, Paul Smith, Krisztina Z. Alapi, Lingyi Wang, Marc R. Mansour, Adele K. Fielding   +14 more
wiley   +1 more source

Veterinarians and NRA legislation [PDF]

Australian Veterinary Journal, 2003
openaire   +1 more source

Long‐term mutational analysis, clonal metrics, and dynamics in patients with chronic idiopathic neutropenia

HemaSphere, Volume 10, Issue 10, October 2026.
Abstract Characterization of the presence and evolution of clonal hematopoiesis (CH) in patients with unexplained cytopenias is fundamental to risk‐stratifying patients and optimizing clinical surveillance for malignant progression. We investigated the mutational spectrum and clonal metrics in a cohort of 256 patients with chronic idiopathic ...
Grigorios Tsaknakis, Irene Mavroudi, Marco Roncador, Anna Maria Perantonaki, Erasmia Boutakoglou, Stavros Papadakis, Anna Gallì, Stamatia Laidou, Charalampos Pontikoglou, Anastasia Chatzidimitriou, Luca Malcovati, Helen A. Papadaki   +11 more
wiley   +1 more source

Protein Engineering-Enabled Cryo-EM Investigation of Small GTPases. [PDF]

J Mol Biol
Hu Z, Patel UR, Glasser E, Koide A, Koide S.   +4 more
europepmc   +1 more source

A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist

HemaSphere, Volume 10, Issue 10, October 2026.
Abstract Acute myeloid leukemia (AML) is a highly aggressive malignancy with poor prognosis, underlining the need for suitable model systems to develop novel treatments. To complement the few existing AML cell lines and restricted primografts, we transplanted more than 100 primary AML samples into immunocompromised mice and generated 23 exceptionally ...
Binje Vick, Vindi Jurinovic, Kristina Kuhbandner, Lena Lagally, Lisa Latzko, Chiara Arnreich, Gerulf Hänel, Amelie Muth, Maximilian Schönung, Arnold Kloos, Maja Rothenberg‐Thurley, Annika M. Dufour, Stephanie Schneider, Lesca M. Holdt, Liliana Mura, Fabian Klein, Annette Frank, Dhruv Mehra, Annika Fröhlich, Johannes W. Bagnoli, Maya C. André, Claudia D. Baldus, Martin Carroll, Christine Dierks, Martin Ebinger, Katharina S. Götze, Pablo Menéndez, Christian Récher, Ambrine Sahal, Jean‐Emmanuel Sarry, Christian Thiede, Talía Velasco‐Hernández, Xiaoyan Wei, Jan H. Klusmann, Wolfgang Enard, Michael von Bergwelt‐Baildon, Wolfgang Hiddemann, Klaus H. Metzeler, Philipp A. Greif, Michael Heuser, Daniel B. Lipka, Marion Subklewe, Sebastian Vosberg, Tobias Herold, Karsten Spiekermann, Irmela Jeremias   +45 more
wiley   +1 more source

Functional characterization of the 9q34.13 locus identifies RAPGEF1 as a candidate gene modulating risk for melanoma and nevi via RAS activation. [PDF]

Am J Hum Genet
Thakur R, Xu M, Thornock AM, Yon J, Anyaso-Samuel S, Lauss M, Rehling T, Bui-Raborn L, Sowards H, Duncan G, Jessop L, Myers T, Chari R, Long E, Funderburk K, Yin J, Hennessey R, Hsieh E, Levin H, Machiela MJ, Zhang T, Jönsson G, Bishop DT, Newton-Bishop J, Nsengimana J, Iles MM, Landi MT, Law MH, Andresson T, Choi J, Zon LI, Shi J, Melanoma Meta-Analysis Consortium, Brown KM.   +33 more
europepmc   +1 more source